189 related articles for article (PubMed ID: 33513829)
1. HuR Protein in Hepatocellular Carcinoma: Implications in Development, Prognosis and Treatment.
Papatheofani V; Levidou G; Sarantis P; Koustas E; Karamouzis MV; Pergaris A; Kouraklis G; Theocharis S
Biomedicines; 2021 Jan; 9(2):. PubMed ID: 33513829
[TBL] [Abstract][Full Text] [Related]
2. Current Evidence and Future Perspectives on HuR and Breast Cancer Development, Prognosis, and Treatment.
Kotta-Loizou I; Vasilopoulos SN; Coutts RH; Theocharis S
Neoplasia; 2016 Nov; 18(11):674-688. PubMed ID: 27764700
[TBL] [Abstract][Full Text] [Related]
3. Hu Antigen R (HuR) Protein Structure, Function and Regulation in Hepatobiliary Tumors.
Lachiondo-Ortega S; Delgado TC; Baños-Jaime B; Velázquez-Cruz A; Díaz-Moreno I; Martínez-Chantar ML
Cancers (Basel); 2022 May; 14(11):. PubMed ID: 35681645
[TBL] [Abstract][Full Text] [Related]
4. Clinical Significance and Biological Role of HuR in Head and Neck Carcinomas.
Levidou G; Kotta-Loizou I; Tasoulas J; Papadopoulos T; Theocharis S
Dis Markers; 2018; 2018():4020937. PubMed ID: 29619127
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance of HuR expression in human malignancy.
Kotta-Loizou I; Giaginis C; Theocharis S
Med Oncol; 2014 Sep; 31(9):161. PubMed ID: 25112469
[TBL] [Abstract][Full Text] [Related]
6. WTAP facilitates progression of hepatocellular carcinoma via m6A-HuR-dependent epigenetic silencing of ETS1.
Chen Y; Peng C; Chen J; Chen D; Yang B; He B; Hu W; Zhang Y; Liu H; Dai L; Xie H; Zhou L; Wu J; Zheng S
Mol Cancer; 2019 Aug; 18(1):127. PubMed ID: 31438961
[TBL] [Abstract][Full Text] [Related]
7. Multiple functions of HuR in urinary tumors.
Zhang F; Cai Z; Lv H; Li W; Liang M; Wei X; Zhou F
J Cancer Res Clin Oncol; 2019 Jan; 145(1):11-18. PubMed ID: 30370480
[TBL] [Abstract][Full Text] [Related]
8. Murine double minute 2 regulates Hu antigen R stability in human liver and colon cancer through NEDDylation.
Embade N; Fernández-Ramos D; Varela-Rey M; Beraza N; Sini M; Gutiérrez de Juan V; Woodhoo A; Martínez-López N; Rodríguez-Iruretagoyena B; Bustamante FJ; de la Hoz AB; Carracedo A; Xirodimas DP; Rodríguez MS; Lu SC; Mato JM; Martínez-Chantar ML
Hepatology; 2012 Apr; 55(4):1237-48. PubMed ID: 22095636
[TBL] [Abstract][Full Text] [Related]
9. HuR Suppresses Fas Expression and Correlates with Patient Outcome in Liver Cancer.
Zhu H; Berkova Z; Mathur R; Sehgal L; Khashab T; Tao RH; Ao X; Feng L; Sabichi AL; Blechacz B; Rashid A; Samaniego F
Mol Cancer Res; 2015 May; 13(5):809-18. PubMed ID: 25678597
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of the embryonic-lethal abnormal vision-like protein HuR in ovarian carcinoma is a prognostic factor and is associated with increased cyclooxygenase 2 expression.
Denkert C; Weichert W; Pest S; Koch I; Licht D; Köbel M; Reles A; Sehouli J; Dietel M; Hauptmann S
Cancer Res; 2004 Jan; 64(1):189-95. PubMed ID: 14729623
[TBL] [Abstract][Full Text] [Related]
11. Emerging role of HuR in inflammatory response in kidney diseases.
Shang J; Zhao Z
Acta Biochim Biophys Sin (Shanghai); 2017 Sep; 49(9):753-763. PubMed ID: 28910975
[TBL] [Abstract][Full Text] [Related]
12. Expression of the ELAV-like protein HuR in human prostate carcinoma is an indicator of disease relapse and linked to COX-2 expression.
Niesporek S; Kristiansen G; Thoma A; Weichert W; Noske A; Buckendahl AC; Jung K; Stephan C; Dietel M; Denkert C
Int J Oncol; 2008 Feb; 32(2):341-7. PubMed ID: 18202756
[TBL] [Abstract][Full Text] [Related]
13. Human antigen R and drug resistance in tumors.
Zhou F; Zhang F; Zhou C; Liang M; Cai Z; Lv H; Li W; Wei X
Invest New Drugs; 2019 Oct; 37(5):1107-1116. PubMed ID: 30612309
[TBL] [Abstract][Full Text] [Related]
14. Human antigen R: A potential therapeutic target for liver diseases.
Liu R; Wu K; Li Y; Sun R; Li X
Pharmacol Res; 2020 May; 155():104684. PubMed ID: 32045667
[TBL] [Abstract][Full Text] [Related]
15. NEDDylation in liver cancer: The regulation of the RNA binding protein Hu antigen R.
Fernández-Ramos D; Martínez-Chantar ML
Pancreatology; 2015 Jul; 15(4 Suppl):S49-54. PubMed ID: 25841271
[TBL] [Abstract][Full Text] [Related]
16. HuR, a key post-transcriptional regulator, and its implication in progression of breast cancer.
Yuan Z; Sanders AJ; Ye L; Jiang WG
Histol Histopathol; 2010 Oct; 25(10):1331-40. PubMed ID: 20712017
[TBL] [Abstract][Full Text] [Related]
17. Elevated Hu-Antigen Receptor (HuR) Expression is Associated with Tumor Aggressiveness and Poor Prognosis but not with COX-2 Expression in Invasive Breast Carcinoma Patients.
Giaginis C; Sampani A; Kotta-Loizou I; Giannopoulou I; Danas E; Politi E; Tsourouflis G; Kouraklis G; Patsouris E; Keramopoulos A; Nakopoulou L; Theocharis S
Pathol Oncol Res; 2018 Jul; 24(3):631-640. PubMed ID: 28808873
[TBL] [Abstract][Full Text] [Related]
18. The cytoskeletal inhibitors latrunculin A and blebbistatin exert antitumorigenic properties in human hepatocellular carcinoma cells by interfering with intracellular HuR trafficking.
Doller A; Badawi A; Schmid T; Brauss T; Pleli T; zu Heringdorf DM; Piiper A; Pfeilschifter J; Eberhardt W
Exp Cell Res; 2015 Jan; 330(1):66-80. PubMed ID: 25240929
[TBL] [Abstract][Full Text] [Related]
19. The RNA Binding Protein HuR: A Promising Drug Target for Anticancer Therapy.
Wu M; Tong CWS; Yan W; To KKW; Cho WCS
Curr Cancer Drug Targets; 2019; 19(5):382-399. PubMed ID: 30381077
[TBL] [Abstract][Full Text] [Related]
20. HuR and post-transcriptional regulation in vascular aging.
Wang W
Sci China Life Sci; 2014 Aug; 57(8):863-6. PubMed ID: 25104461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
